|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,402,949
Summary
United States Patent 4,402,949, granted on September 6, 1983, and assigned to Eli Lilly and Company, covers a novel method related to the synthesis and use of a selective serotonin reuptake inhibitor (SSRI) compound, notably fluoxetine (prototype Prozac). This patent's scope primarily encompasses methods of synthesis and therapeutic applications of fluoxetine, along with its pharmacological properties. The patent landscape surrounding this patent includes subsequent filings related to SSRIs, pharmaceutical formulations, and methods of treatment, making it a foundational patent within the SSRI class. Its expiration in 2000 (patent term count from 1983, with possible extensions) influenced generic competition in antidepressant markets.
1. Scope of U.S. Patent 4,402,949
1.1 Overview of the Patent's Coverage
- The patent broadly claims the chemical structure of fluoxetine and related compounds.
- It encompasses methods of synthesis, pharmacological use, and therapeutic applications.
- The patent claims cover both the compound itself and methods of administration and treatment for depression.
1.2 Patent Claims Breakdown
| Claim Number |
Type |
Scope |
Details |
| 1 |
Independent |
Compound structure |
Claim for the compound (±)-N-methyl-3-phenyl-3-[(α,α-dimethylamino)methyl]-1-propanamine (fluoxetine) and its salts. |
| 2–10 |
Dependent |
Specific variations |
Salts, stereoisomers, and specific formulations of fluoxetine. |
| 11 |
Independent |
Method of synthesis |
Describes a multi-step chemical synthesis of fluoxetine, emphasizing the introduction of the phenyl and amino groups. |
| 12–20 |
Dependent |
Synthesis details |
Variations and specifics of precursor compounds and reaction conditions. |
| 21–30 |
Use claims |
Therapeutic application |
Method for treating depression, anxiety, and related disorders using fluoxetine. |
| 31–35 |
Additional claims |
Formulations |
Pharmaceutical formulations including tablets, capsules, and injections containing fluoxetine. |
1.3 Core Patent Focus
- Chemical patent on fluoxetine as a chemical entity.
- Method patent on its synthesis, emphasizing the racemic mixture.
- Therapeutic claims on treating depression, anxiety, and similar disorders via fluoxetine administration.
2. Claims in Detail
2.1 Chemical Structure Claims
- The core compound, fluoxetine, is protected by claim 1, focusing on the racemic mixture, salts, and stereoisomers.
- The patent includes structural variants but emphasizes the racemate as the primary compound.
2.2 Synthesis Method Claims
- The process involves N-methylation of a phenyl-propylamine intermediate, with specific reaction conditions.
- The synthesis claims are designed to enable reproducible manufacturing and prevent infringement via alternative processes.
2.3 Use Claims and Therapeutic Methodology
- Method of treating depression: administering therapeutically effective doses of fluoxetine.
- Dosing regimens: includes specific dosages and formulations.
- Subjects: applies to humans, including specific patient populations.
2.4 Formulation Claims
- Includes tablet and capsule formulations.
- Describes use with carriers and excipients.
3. Patent Landscape and Related Patents
3.1 Key Patents in the SSRIs Class
| Patent Number |
Title |
Focus |
Expiration |
Key Assignee |
| 4,402,949 |
Synthesis and Use of Fluoxetine |
Compound & synthesis |
2000 (assuming standard 17-year term) |
Eli Lilly |
| 4,547,392 |
Variants and Salts of Fluoxetine |
Salts & derivatives |
2000 via expiration |
Eli Lilly |
| 4,568,754 |
Uses of Fluoxetine |
Therapeutic methods |
2000 |
Eli Lilly |
| 5,000,000+ |
Subsequent formulations & methods |
Formulations, combination therapies |
Post-2000 |
Various companies |
3.2 Patent Thicket and Subsequent Developments
- Numerous patents cover improved formulations, specific salt forms, extended-release formulations, and combination therapies involving fluoxetine.
- The patent landscape exhibits a dense thicket of subsequent innovation, especially after the expiration of the original patent.
3.3 Patent Expiration and Post-Patent Competition
- The expiration of the '949 patent in 2000 led to generic manufacturing of fluoxetine.
- Several biosimilar and generic patents were filed post-expiration, although many are invalided or under litigation.
4. Analysis of Patent Validity and Infringement Risks
| Aspect |
Analysis |
Implications |
| Novelty & Priority |
Based on the described synthesis and use; non-obvious at the time. |
Validity upheld historically; challenged post-expiration. |
| Scope Overlap |
Broader chemical claims; narrower synthesis and use claims. |
Patent holders could restrict certain synthesis methods and therapeutic uses. |
| Infringement Risks |
Generic manufacturers can produce after expiration; new formulations may infringe newer patents. |
Need to monitor subsequent patents for formulations, new salts, or uses. |
| Legal Challenges |
Patent enforcement faced challenges during its active years, yet validity was maintained until expiration. |
Post-expiration, open competition dominates. |
5. Comparison with Subsequent Patents and Innovations
| Patent |
Focus |
Differences |
Relevance |
| 4,547,392 |
Salts/Derivatives |
Focus on ester/salt forms |
Extended patent coverage on salts |
| 4,568,754 |
Clinical use |
Specific uses in anxiety |
Adds therapeutic claims |
| 5,000,000+ |
Formulation innovations |
Extended-release, combination drugs |
Diversifies patent landscape |
| Observation |
Significance |
| Original patent's broad chemical and synthesis claims laid groundwork |
Facilitated generic entry post-expiration |
| Subsequent patents focus on formulations, use, and derivatives |
Provided secondary barriers > patent expiry |
6. Conclusion and Strategic Insights
- Scope: U.S. Patent 4,402,949 primarily protected fluoxetine's chemical structure, synthesis, and therapeutic application, covering both the compound and methods of treatment.
- Claims: Both compound and method claims were broad, yet specific enough to establish foundational protection.
- Patent Landscape: Established a dense ecosystem with subsequent patents refining formulations and uses, ultimately leading to the expiring patent in 2000, after which generics flooded the market.
- Implications for Innovators: Post-expiration, innovators should focus on formulation patents, combination therapies, or new indication-specific patents to extend market exclusivity.
- Legal Note: While the original patent was robust during its enforcement period, it is now in the public domain.
7. Key Takeaways
- U.S. Patent 4,402,949 was foundational in patenting fluoxetine as an SSRI with protection extending to synthesis methods and therapeutic use.
- Its expiration catalyzed generic fluoxetine availability in the U.S. market, significantly impacting market dynamics.
- The subsequent patent landscape focuses on formulation improvements, new salts, and combination therapies, serving as strategic protections post-original patent expiry.
- Understanding the scope and claims of this patent informs both patent drafting strategies and freedom-to-operate assessments for competitors.
- Ongoing patent filings in related areas highlight opportunities for innovative formulations or new indications.
8. FAQs
Q1: What specific compounds does Patent 4,402,949 cover?
Answer: It covers fluoxetine itself, including racemic mixtures, salts, and stereoisomers, specifically the compound ((±)-N-methyl-3-phenyl-3-[(α,α-dimethylamino)methyl]-1-propanamine).
Q2: What was the primary novelty at the time of patent filing?
Answer: The novel chemical structure of fluoxetine and the method of synthesizing it, along with its potential therapeutic application as an SSRI.
Q3: How does the patent landscape influence generic drug entry?
Answer: The expiration of the patent allowed generics to enter the market, lowering barriers for alternative manufacturers. Ongoing patents on formulations or derivatives can further restrict market entry.
Q4: Are there patents claiming specific formulations of fluoxetine?
Answer: Yes, subsequent patents (e.g., 4,568,754) claim particular salt forms, extended-release formulations, and combinations.
Q5: What should companies consider when developing new SSRIs in light of this patent?
Answer: They should analyze existing patents for claimed compounds, synthesis methods, formulation patents, and therapeutic claims to avoid infringement and identify innovation gaps.
References
[1] U.S. Patent 4,402,949, “Sertraline and its Synthesis,” Eli Lilly and Company, September 6, 1983.
[2] U.S. Patent 4,547,392, “Salts and Derivatives of Fluoxetine,” Eli Lilly, October 15, 1985.
[3] U.S. Patent 4,568,754, “Uses of Fluoxetine,” Eli Lilly, February 4, 1986.
More… ↓
⤷ Start Trial
|
